검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Certolizumab Pegol (CDP870) |
Overview Company | UCB Pharma |
Overview Modality | ANTIBODY |
Overview Target | Crohn's Disease |
Overview Indication | Crohn's Disease |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers (including sFlt-1/PlGF), standardized endpoints, and detailed safety follow-up are needed before a |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study.. To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular-course juvenile idiopathic arthritis (pcJIA). Pediatric Arthritis Study of Certolizumab Pe… |
Clinical Primary efficacy | ORR 5% |
Clinical ORR | 5.00% |
Clinical Result source | ClinicalTrials.gov NCT00845663 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Certolizumab Pegol (CDP870) |
Overview Company | UCB Pharma |
Overview Modality | ANTIBODY |
Overview Target | Crohn's Disease |
Overview Indication | Crohn's Disease |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
MoA Mechanism | Targeted immunotherapies provide effective interventions by disrupting these cytokine-driven pathway |
MoA Biomarker | biomarkers (including sFlt-1/PlGF), standardized endpoints, and detailed safety follow-up are needed before a |
PK/PD Half-life | 14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Pharmacokinetics, effectiveness and safety of certolizumab pegol in children and adolescents with active juvenile idiopathic arthritis: 9+-year results from a multicenter, open-label study.. To assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular-course juvenile idiopathic arthritis (pcJIA). Pediatric Arthritis Study of Certolizumab Pe… |
Clinical Primary efficacy | ORR 5% |
Clinical ORR | 5.00% |
Clinical Result source | ClinicalTrials.gov NCT00845663 |
Clinical Data Tier / Score | A · 40 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교